Get the Stockscreener App
131.65
0.62%
0.81
After Hours:
132.00
0.35
+0.27%
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $131.65, with a volume of 5.52M.
It is up +0.62% in the last 24 hours and down -6.17% over the past month.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$130.84
Open:
$130
24h Volume:
5.52M
Relative Volume:
0.85
Market Cap:
$163.40B
Revenue:
$29.45B
Net Income/Loss:
$8.51B
P/E Ratio:
19.41
EPS:
6.7823
Net Cash Flow:
$9.46B
1W Performance:
+0.96%
1M Performance:
-6.17%
6M Performance:
+9.90%
1Y Performance:
+27.51%
1-Day Range:
$129.01
$132.36
1-Week Range:
$127.64
$132.36
52-Week Range:
$95.30
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
131.65 | 163.40B | 29.45B | 8.51B | 9.46B | 6.7823 |
LLY
Lilly Eli Co
|
963.33 | 862.01B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
227.19 | 546.90B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
206.60 | 365.43B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
184.74 | 286.50B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
146.57 | 279.67B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | Jefferies | Buy |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-11-26 | Reiterated | Needham | Buy |
| Jan-07-26 | Resumed | UBS | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Aug-19-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Aug-08-25 | Upgrade | Truist | Hold → Buy |
| Jul-25-25 | Upgrade | Needham | Hold → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Benjamin Edwards Inc. Has $16.60 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
FDA Priority Review For New HIV Combo Might Change The Case For Investing In Gilead Sciences (GILD) - simplywall.st
Strs Ohio Reduces Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Robertson Stephens Wealth Management LLC Has $6.27 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead’s HIV Priority Review And Arcellx Deal Refocus Long‑Term Story - Yahoo Finance
The Freelux Project Announces “The Butch Queen’s Brunch & Conversations Tour” Powered by Gilead Sciences - GLAAD
Gilead Sciences, Inc. $GILD Shares Sold by New York State Teachers Retirement System - MarketBeat
Oppenheimer & Co. Inc. Cuts Position in Gilead Sciences, Inc. $GILD - MarketBeat
Jennison Associates LLC Buys 741,044 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
US Bancorp DE Has $105.44 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences - The AI Journal
Danske Bank A S Sells 45,529 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Fifth Third Bancorp Increases Position in Gilead Sciences, Inc. $GILD - MarketBeat
GC Wealth Management RIA LLC Reduces Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S Cash Flow – TSX:GILD - TradingView
Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S Revenue Breakdown – TSX:GILD - TradingView
Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Gilead Sciences Annual Meeting: Directors, Pay Win Big; Pipeline Launches and Acquisitions Highlighted - MarketBeat
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Is Gilead Sciences, Inc. (GILD) A Good Stock To Buy Now? - Insider Monkey
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir - European AIDS Treatment Group
Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish? - Barchart
Gilead Sciences, Inc. $GILD Shares Sold by Verity Asset Management Inc. - MarketBeat
Gilead Sciences, Inc. $GILD Position Trimmed by State of New Jersey Common Pension Fund D - MarketBeat
Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
FY2026 EPS Estimates for Gilead Sciences Reduced by Analyst - MarketBeat
Kymera Therapeutics (NASDAQ: KYMR) Q1 2026 results and $45M Gilead milestone - Stock Titan
Is It Time To Revisit Gilead Sciences (GILD) After Recent Share Price Pullback - Yahoo Finance
Insider Sell: Daniel O'Day Sells 10,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
Gilead Sciences (NASDAQ:GILD) CEO Sells $1,291,600.00 in Stock - MarketBeat
Vanguard reports 93.3M-share, 7.51% stake in Gilead Sciences (NASDAQ: GILD) - Stock Titan
Gilead Sciences CEO Daniel O’Day sells over $1.29m in stock - Investing.com Nigeria
Gilead (NASDAQ: GILD) CEO sells 10,000 shares in planned trade - Stock Titan
Assessing Whether Gilead Sciences (GILD) Looks Undervalued After Recent Share Price Performance - simplywall.st
Gilead Sciences Stock: Three Acquisitions, Four Launches, and a 20% Discount to Wall Street’s Target - TIKR.com
U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir - BioSpace
GILD: Gilead's New HIV Treatment Gains FDA Acceptance - GuruFocus
Kymera Therapeutics earnings on deck after Gilead deal milestone By Investing.com - Investing.com Nigeria
Morgan Stanley Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Gilead Sciences stock edges higher as FDA grants priority review for HIV treatment - Traders Union
FDA accepts Gilead’s HIV treatment combination for review - Investing.com
Gilead Sciences, Inc. (NASDAQ:GILD) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Gilead Sciences (GILD) Closes $7.8B Arcellx Buyout — What Investors Need to Know - MEXC
Daniel O'Day (GILD) files Form 144 to sell 10,000 performance shares - Stock Titan
Rheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Gilead Sciences (GILD) Stock Lands $7.8B Arcellx Deal — Is This the Buy Opportunity? - CoinCentral
Gilead Sciences, Inc. completed the acquisition of 77.2% stake in Arcellx, Inc. from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR One Capital Management, LP, and others. - marketscreener.com
Gilead Sciences Crosses Critical Breakout Level. The Stock Can Gain 35% From Here. - Barron's
Gilead Sciences (GILD) Completes Acquisition of Arcellx, Inc. - GuruFocus
Gilead Sciences completes acquisition of Arcellx ahead of potential commercial launch of Anito-cel - marketscreener.com
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
3.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):